Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

45.85
-1.6000-3.37%
Post-market: 45.850.00000.00%19:30 EDT
Volume:748.89K
Turnover:34.79M
Market Cap:2.66B
PE:-23.95
High:47.82
Open:47.71
Low:45.79
Close:47.45
52wk High:59.68
52wk Low:42.45
Shares:58.04M
Float Shares:51.67M
Volume Ratio:1.29
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9145
EPS(LYR):-0.6829
ROE:-10.49%
ROA:0.39%
PB:2.58
PE(LYR):-67.14

Loading ...

Supernus Sr. VP of IP and CSO Padmanabh P. Bhatt disposes of USD 5.4 million in common shares

Reuters
·
Mar 19

Supernus CEO Jack A. Khattar disposes of USD 1.75 million in common shares

Reuters
·
Mar 17

Supernus Director Frederick M. Hudson Disposes of USD 271,226 in Common Shares

Reuters
·
Mar 17

Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns

Simply Wall St.
·
Mar 16

Supernus Pharmaceuticals Braces for 2025 U.S. Drug Pricing Orders and MFN Rules That Threaten Revenues and Global Expansion

TIPRANKS
·
Mar 04

Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge?

Simply Wall St.
·
Mar 03

Supernus Pharmaceuticals Balances Record Sales With Rising Costs

TIPRANKS
·
Mar 03

Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook

Simply Wall St.
·
Mar 02

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oxford BioMedica (OtherOXBDF), Valneva (VALN) and Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
Feb 27

Supernus Pharmaceuticals (SUPN) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
Feb 25

Stock Track | Supernus Pharmaceuticals Soars 8.22% Intraday on Better-Than-Expected Q4 Results and Strong Guidance

Stock Track
·
Feb 25

Stock Track | Supernus Pharmaceuticals Soars 6.75% in Pre-market on Better-than-Expected Q4 Results and Strong Guidance

Stock Track
·
Feb 25

Supernus Pharmaceuticals Raises CEO Khattar Base Salary to $1.07 Million

Reuters
·
Feb 25

Supernus Q4 total revenues hit USD 211.6 million, up 21%

Reuters
·
Feb 25

Supernus Pharmaceuticals Q4 EPS $(0.07) Beats $(0.16) Estimate, Sales $211.572M Beat $195.004M Estimate

Benzinga Earnings
·
Feb 25

Stock Track | Supernus Pharmaceuticals Soars 5.89% on Strong Q4 Results and Upbeat Outlook

Stock Track
·
Feb 25

BRIEF-Supernus Pharmaceuticals Q4 Product Sales USD 158.1 Million

Reuters
·
Feb 25

Supernus Pharmaceuticals Q4 EPS USD -0.07

THOMSON REUTERS
·
Feb 25

Supernus Pharmaceuticals to Participate in March Investor Conferences

GlobeNewswire
·
Feb 24

Supernus Pharmaceuticals Director Bethany Sensenig Disposes of Common Shares

Reuters
·
Feb 24